A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 263-267

  Eroglu, Zeynep ^a   Fruehauf, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder Cancer; GEMOX; Oxaliplatin; Phase II; Renal insufficiency

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; URINARY BLADDER NEOPLASMS;

EID: 84879796431     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2178-x     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63:11-30
2. Kim JJ (2012) Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 13:147-152
3. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055
4. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066-1073
5. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
6. Xu N, Zhang XC, Xiong JP, Fang WJ, Yu LF, Qian J, Zhang L (2007) A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer 7:98
7. Redman BG, Smith DC, Flaherty L, Du W, Hussain M (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844-1848
8. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern cooperative oncology group study. J Clin Oncol 18:1058-1061
9. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH (2006) Impact of renal impairment on eligibility for adjuvant cisplatin based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506-513
10. Mottet-Auselo N, Bons-Rosset F, Costa P, Louis JF, Navratil H (1993) Carboplatin and urothelial tumors. Oncology 50(Suppl 2):28-36
11. Kweekel DW, Gelderblom H, Guchelaar H-J (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105
12. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effects of 2',2'-difluorodeoxycytidine [gemcitabine] in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumors: revised RECIST guideline [version 1.1]. Eur J Cancer 45:228-247
14. Castagneto B, Zai S, Marenco D, Bertetto O, Repetto L, Scaltriti L, Mencoboni M, Ferraris V, Botta M (2004) Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology. 67:27-32
15. Culine S, Rebillard X, Iborra F, Mottet N, Faix A, Ayuso D, Pinguet F (2003) Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res 23:1903-1906
16. Mir O, Alexandre J, Ropert S, Amsellem-Ouazana D, Flam T, Beuzeboc P, Zerbib M, Debré B, Guillevin L, Goldwasser F (2005) Combination of gemcitabine and oxaliplatin in urotheliancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 16:1017-1021
17. Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J (2007) Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 18:1359-1362
18. Culine S, Flechon A, Guillot A, Le Moulec S, Pouessel D, Rolland F, Ravaud A, Houédé N, Mignot L, Joly F, Oudard S, Gourgou S (2011) Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized Phase 2 study of the French Genitourinary Tumor Group. Eur Urol 60:1251-1257
19. Theodore C, Bidault F, Bouvet-Forteau N, Abdelatif M, Fizazi K, di Palma M, Wibault P, de Crevoisier R, Laplanche A (2006) A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 17:990-994
20. Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J (2011) Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol 29:2432-2438
21. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191-199
22. NCT01487915: Gemcitabine-carboplatin versus gemcitabine-oxaliplatin in cisplatin un-fit advanced urothelial carcinoma: Randomized Phase II study. From clinicaltrials.gov accessed January 2013: http://www.clinicaltrials.gov/ct2/ show/NCT01487915